Cross-Sector entity
Of the tracked stories, 4 of 12 also mention OpenAI, the most common co-covered peer. Across a 186-day span, the pace is roughly 0.5 stories per week. The busiest single day carried 4. Coverage clusters in funding, which accounts for 6 of those 12, with the remainder spread across 3 other categories.
12 verified stories tracked
Last mentioned: 3d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 12 also mention OpenAI, the most common co-covered peer. Across a 186-day span, the pace is roughly 0.5 stories per week. The busiest single day carried 4. Coverage clusters in funding, which accounts for 6 of those 12, with the remainder spread across 3 other categories. Negative sentiment appears in 17% of the tracked stories. Each carries 3.7 original sources on average. We currently track 12 Cross-Sector stories that mention PitchBook, published between February 18, 2026 and August 22, 2026.
Computed from the 12 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PitchBook. Shared-story counts are live from our verified record — not editorial picks.
DZYNE Predicted Revenue of $300M
Ondas expects DZYNE's revenue to grow to $300 million in 2027, underlining aggressive expansion.
DZYNE Technologies Acquisition Announced
Ondas announces a definitive agreement to acquire DZYNE Technologies for $875.8 million in cash and stock, creating a full-service autonomous defense platform.
Ominisys Acquisition Completed
Ondas finalizes the acquisition of Ominisys, expanding its autonomous systems portfolio.
Anticipated Deployment
Expected increase in stake sizes for OpenAI and SpaceX ahead of rumored public filings.
Concentration hits record high
Experienced firms capture 91% of all VC capital raised in Q1 2026, the highest level in PitchBook's dataset.
Fund Closing
Thrive Capital officially closes the $10B fund, marking a record for the firm.
Thrive X Launch
Initial reports surface regarding the $10 billion target for the new venture vehicle.
IPO Window
Market analysts project potential IPO dates for major Thrive portfolio companies.
DZYNE Expected Revenue of $191M
DZYNE is projected to generate $191 million in revenue for the full year 2026.
Previous Fund Cycle
Thrive Capital manages its previous multi-billion dollar fund, establishing core positions in AI.
BBG Ventures closes new fund
Nisha Dua and Susan Lyne complete a fundraise for BBG Ventures, relying on their track record and niche focus.
Market downturn begins
Tech stocks sell off, the IPO window shuts, and LPs become cautious, making fundraising extremely hard for emerging VC managers.
PitchBook data shows California captured $366B in 2026 venture funding—90% of the U.S. total—while AI took 86 cents of every VC dollar. For finance professionals, the state's record haul raises concentration risk and tax-policy questions even as it cements California as private-market ground zero.
Source: Nilesh Christopher · Paul Kiernan
The $3.8 billion raised by MENA startups in 2025 was a record, yet the region’s venture ecosystem still lacks the exit opportunities that fuel sustainable growth. Without a stronger pipeline of IPOs and acquisitions, the funding boom risks becoming a bubble of unfilled potential.
Despite a 74% YoY surge to $3.8 billion, MENA’s venture capital market captured well under 1% of global funding in 2025. The lopsided concentration in Saudi Arabia and the UAE and the absence of a liquid exit pipeline raise urgent questions for institutional investors eyeing emerging market exposure.
Source: arabnews.com · Arab News
The biotech venture market is splitting in two: established clinical-stage companies are raising megafunds at a blistering pace, while preclinical and seed-stage biotechs face a deepening funding winter. The contrast underscores a structural shift in startup financing strategies.
Biotech venture capital surged to $9.1 billion in the first half of 2026, yet the majority flowed to companies with drugs already in clinical testing, leaving preclinical-stage firms facing a severe funding drought. This divergence threatens the future drug pipeline even as IPO and M&A markets boom.
Source: Gwendolyn Wu · BioPharma Dive
Ondas Inc.’s acquisition of DZYNE Technologies for $875.8 million in cash and stock consolidates a leading autonomous military drone and counter-UAS portfolio, positioning the company as a major contender in the reshaped American defense industrial base. The deal combines DZYNE’s reconnaissance and surveillance UAVs with Ondas’s communications systems, targeting $525 million in combined revenue this year amid surging Pentagon demand for autonomous warfare capabilities.
Source: latimes.com · themiddlemarket.com
With 91% of capital committed to established VC firms in Q1 2026, the LP market signals unprecedented risk aversion — a trend that could undermine the venture ecosystem's ability to generate outsized returns and back breakthrough startups.
Emerging VC fund managers are getting squeezed as LPs pour record capital into established firms. Nisha Dua of BBG Ventures shares how to navigate the crunch and why niche focus still wins.
Source: Melia Russell · Business Insider
Thrive Capital has closed a record-breaking $10 billion venture fund, Thrive X, nearly doubling its previous fundraising efforts. The capital injection is strategically positioned to back high-growth leaders in artificial intelligence and space technology, specifically targeting pre-IPO positions in OpenAI and SpaceX.
Thrive Capital has closed a record-breaking $10 billion venture fund, Thrive X, significantly expanding its capacity to back late-stage leaders in artificial intelligence and space technology. The massive capital injection is strategically timed to capitalize on anticipated public market debuts for industry titans like OpenAI and SpaceX.
Thrive Capital has closed its latest venture fund, Thrive X, at a record $10 billion, nearly doubling its previous raise. The fund is strategically positioned to capitalize on the growth of AI and space technologies, specifically targeting high-profile portfolio companies like OpenAI and SpaceX.
Thrive Capital has closed its record-breaking $10 billion 'Thrive X' fund, nearly doubling its previous capital raise. The vehicle is strategically positioned to back category-defining leaders in artificial intelligence and space technology, specifically targeting late-stage growth in portfolio anchors like OpenAI and SpaceX.
Source: Pensions & Investments · PitchBook
